Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).
• Approved EGFR tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, and afatinib have transformed treatment for EGFR-mutated NSCLC, improving survival and quality of life.
• Resistance to first- and second-generation TKIs often arises, notably through the EGFR T790M mutation.

Purpose of the Study:

• To review the biological mechanisms, diagnostic evaluations, and therapeutic strategies for NSCLC harboring the EGFR T790M resistance mutation.
• To consolidate current scientific evidence on managing EGFR T790M-positive NSCLC.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of data on EGFR mutation identification and TKI efficacy.
• Synthesis of information on resistance mechanisms and novel therapeutic agents.

Main Results:

• EGFR TKIs (afatinib, erlotinib, gefitinib) are effective first-line treatments for specific EGFR mutations (exon 19 deletions, L858R).
• The EGFR T790M mutation is a primary mechanism of acquired resistance to these therapies.
• Third-generation EGFR-mutant-selective TKIs (osimertinib, rociletinib, olmutinib) demonstrate significant activity against the T790M mutation.

Conclusions:

• Targeted therapy has revolutionized EGFR-mutated NSCLC treatment.
• Understanding and targeting resistance mechanisms, particularly the EGFR T790M mutation, is crucial for improving long-term patient outcomes.
• Third-generation TKIs represent a promising therapeutic advance for patients who develop T790M-mediated resistance.